vs
Axogen, Inc.（AXGN）与康美（CNMD）财务数据对比。点击上方公司名可切换其他公司
康美的季度营收约是Axogen, Inc.的6.2倍（$373.2M vs $59.9M）。Axogen, Inc.同比增速更快（21.3% vs 7.9%）。康美自由现金流更多（$41.2M vs $1.8M）。过去两年Axogen, Inc.的营收复合增速更高（20.3% vs 9.3%）
Axogen总部位于美国佛罗里达州阿拉楚阿，是外科解决方案提供商，专注开发周围神经损伤修复相关产品，涵盖人体组织移植物、神经连接器、软组织膜等，旗下AVANCE细胞移植技术可模拟人体神经结构，临床数据显示其产品帮助87%的周围神经损伤患者实现感觉与运动功能恢复，2013年完成1800万美元首次公开募股。
康美公司是一家上市的美国医疗设备制造商，主营骨科、腹腔镜、普通外科相关医疗器械以及各类患者护理产品，总部现位于佛罗里达州拉戈，2022年7月前设于纽约州尤蒂卡。该品牌秉持以人为本的文化，以助力医疗合作方及其服务的患者为核心使命，在美国和墨西哥都设有生产基地。
AXGN vs CNMD — 直观对比
营收规模更大
CNMD
是对方的6.2倍
$59.9M
营收增速更快
AXGN
高出13.4%
7.9%
自由现金流更多
CNMD
多$39.4M
$1.8M
两年增速更快
AXGN
近两年复合增速
9.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $59.9M | $373.2M |
| 净利润 | $-13.2M | — |
| 毛利率 | 74.1% | 58.5% |
| 营业利润率 | -16.3% | 9.8% |
| 净利率 | -22.0% | — |
| 营收同比 | 21.3% | 7.9% |
| 净利润同比 | -3023.6% | — |
| 每股收益（稀释后） | $-0.28 | $0.54 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXGNCNMD
| Q4 25 | $59.9M | $373.2M | ||
| Q3 25 | $60.1M | $337.9M | ||
| Q2 25 | $56.7M | $342.3M | ||
| Q1 25 | $48.6M | $321.3M | ||
| Q4 24 | $49.4M | $345.9M | ||
| Q3 24 | $48.6M | $316.7M | ||
| Q2 24 | $47.9M | $332.1M | ||
| Q1 24 | $41.4M | $312.3M |
净利润AXGNCNMD
| Q4 25 | $-13.2M | — | ||
| Q3 25 | $708.0K | $2.9M | ||
| Q2 25 | $579.0K | $21.4M | ||
| Q1 25 | $-3.8M | $6.0M | ||
| Q4 24 | $450.0K | — | ||
| Q3 24 | $-1.9M | $49.0M | ||
| Q2 24 | $-1.9M | $30.0M | ||
| Q1 24 | $-6.6M | $19.7M |
毛利率AXGNCNMD
| Q4 25 | 74.1% | 58.5% | ||
| Q3 25 | 76.6% | 49.2% | ||
| Q2 25 | 74.2% | 55.0% | ||
| Q1 25 | 71.9% | 55.3% | ||
| Q4 24 | 76.1% | 57.3% | ||
| Q3 24 | 74.9% | 56.5% | ||
| Q2 24 | 73.8% | 55.3% | ||
| Q1 24 | 78.8% | 55.1% |
营业利润率AXGNCNMD
| Q4 25 | -16.3% | 9.8% | ||
| Q3 25 | 3.2% | 3.5% | ||
| Q2 25 | 3.0% | 11.1% | ||
| Q1 25 | -3.4% | 5.0% | ||
| Q4 24 | 4.1% | 15.2% | ||
| Q3 24 | -0.6% | 20.7% | ||
| Q2 24 | -0.9% | 14.2% | ||
| Q1 24 | -11.0% | 11.2% |
净利率AXGNCNMD
| Q4 25 | -22.0% | — | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 1.0% | 6.3% | ||
| Q1 25 | -7.9% | 1.9% | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | -3.8% | 15.5% | ||
| Q2 24 | -4.0% | 9.0% | ||
| Q1 24 | -16.0% | 6.3% |
每股收益（稀释后）AXGNCNMD
| Q4 25 | $-0.28 | $0.54 | ||
| Q3 25 | $0.01 | $0.09 | ||
| Q2 25 | $0.01 | $0.69 | ||
| Q1 25 | $-0.08 | $0.19 | ||
| Q4 24 | $-0.00 | $1.09 | ||
| Q3 24 | $-0.04 | $1.57 | ||
| Q2 24 | $-0.04 | $0.96 | ||
| Q1 24 | $-0.15 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.5M | — |
| 总债务越低越好 | $48.4M | $834.2M |
| 股东权益账面价值 | $128.8M | $1.0B |
| 总资产 | $221.7M | $2.3B |
| 负债/权益比越低杠杆越低 | 0.38× | 0.81× |
8季度趋势，按日历期对齐
现金及短期投资AXGNCNMD
| Q4 25 | $41.5M | — | ||
| Q3 25 | $35.8M | — | ||
| Q2 25 | $29.9M | — | ||
| Q1 25 | $22.1M | — | ||
| Q4 24 | $33.5M | — | ||
| Q3 24 | $24.5M | — | ||
| Q2 24 | $21.1M | — | ||
| Q1 24 | $17.6M | — |
总债务AXGNCNMD
| Q4 25 | $48.4M | $834.2M | ||
| Q3 25 | $48.2M | $853.0M | ||
| Q2 25 | $47.9M | $881.1M | ||
| Q1 25 | $47.7M | $891.4M | ||
| Q4 24 | $47.5M | $905.1M | ||
| Q3 24 | $47.3M | $940.1M | ||
| Q2 24 | $47.0M | $965.2M | ||
| Q1 24 | $46.8M | $990.1M |
股东权益AXGNCNMD
| Q4 25 | $128.8M | $1.0B | ||
| Q3 25 | $120.8M | $1.0B | ||
| Q2 25 | $112.3M | $1.0B | ||
| Q1 25 | $105.4M | $977.6M | ||
| Q4 24 | $103.9M | $962.7M | ||
| Q3 24 | $99.4M | $932.9M | ||
| Q2 24 | $95.7M | $881.8M | ||
| Q1 24 | $93.2M | $854.7M |
总资产AXGNCNMD
| Q4 25 | $221.7M | $2.3B | ||
| Q3 25 | $216.4M | $2.3B | ||
| Q2 25 | $205.5M | $2.3B | ||
| Q1 25 | $196.2M | $2.3B | ||
| Q4 24 | $203.7M | $2.3B | ||
| Q3 24 | $192.0M | $2.3B | ||
| Q2 24 | $188.9M | $2.3B | ||
| Q1 24 | $186.5M | $2.3B |
负债/权益比AXGNCNMD
| Q4 25 | 0.38× | 0.81× | ||
| Q3 25 | 0.40× | 0.85× | ||
| Q2 25 | 0.43× | 0.88× | ||
| Q1 25 | 0.45× | 0.91× | ||
| Q4 24 | 0.46× | 0.94× | ||
| Q3 24 | 0.48× | 1.01× | ||
| Q2 24 | 0.49× | 1.09× | ||
| Q1 24 | 0.50× | 1.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | $46.3M |
| 自由现金流经营现金流 - 资本支出 | $1.8M | $41.2M |
| 自由现金流率自由现金流/营收 | 3.0% | 11.0% |
| 资本支出强度资本支出/营收 | 2.1% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-2.9M | $150.9M |
8季度趋势，按日历期对齐
经营现金流AXGNCNMD
| Q4 25 | $3.0M | $46.3M | ||
| Q3 25 | $3.2M | $53.7M | ||
| Q2 25 | $7.7M | $29.1M | ||
| Q1 25 | $-13.2M | $41.5M | ||
| Q4 24 | $8.7M | $43.3M | ||
| Q3 24 | $3.9M | $51.2M | ||
| Q2 24 | $4.2M | $43.3M | ||
| Q1 24 | $-12.3M | $29.1M |
自由现金流AXGNCNMD
| Q4 25 | $1.8M | $41.2M | ||
| Q3 25 | $1.7M | $48.5M | ||
| Q2 25 | $7.0M | $23.4M | ||
| Q1 25 | $-13.4M | $37.8M | ||
| Q4 24 | $8.1M | $39.3M | ||
| Q3 24 | $3.3M | $47.8M | ||
| Q2 24 | $3.3M | $39.7M | ||
| Q1 24 | $-13.2M | $27.1M |
自由现金流率AXGNCNMD
| Q4 25 | 3.0% | 11.0% | ||
| Q3 25 | 2.8% | 14.4% | ||
| Q2 25 | 12.4% | 6.8% | ||
| Q1 25 | -27.7% | 11.8% | ||
| Q4 24 | 16.3% | 11.4% | ||
| Q3 24 | 6.8% | 15.1% | ||
| Q2 24 | 6.8% | 12.0% | ||
| Q1 24 | -31.9% | 8.7% |
资本支出强度AXGNCNMD
| Q4 25 | 2.1% | 1.4% | ||
| Q3 25 | 2.5% | 1.5% | ||
| Q2 25 | 1.3% | 1.7% | ||
| Q1 25 | 0.5% | 1.2% | ||
| Q4 24 | 1.4% | 1.2% | ||
| Q3 24 | 1.2% | 1.1% | ||
| Q2 24 | 1.9% | 1.1% | ||
| Q1 24 | 2.2% | 0.7% |
现金转化率AXGNCNMD
| Q4 25 | — | — | ||
| Q3 25 | 4.55× | 18.78× | ||
| Q2 25 | 13.35× | 1.36× | ||
| Q1 25 | — | 6.88× | ||
| Q4 24 | 19.41× | — | ||
| Q3 24 | — | 1.05× | ||
| Q2 24 | — | 1.44× | ||
| Q1 24 | — | 1.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXGN
暂无分部数据
CNMD
| Transferred At Point In Time | $358.5M | 96% |
| Transferred Over Time | $14.7M | 4% |
